Risk-treatment mismatch in the pharmacotherapy of heart failure
Lee DS, Tu JV, Juurlink DN, Alter DA, Ko DT, Austin PC, Chong A, Stukel TA, Levy D, Laupacis A. JAMA. 2005; 294(10):1240-7.
Publications
How many patients with heart failure are eligible for cardiac resynchronization? Insights from two prospective cohorts
McAlister FA, Tu JV, Newman A, Lee DS, Kimber S, Cujec B, Armstrong PW. Eur Heart J. 2006; 27(3):323-9. Epub 2005 Aug 16.
Do case-generic measures of queue performance for bypass surgery accurately reflect the waiting-list experiences of those most urgent?
Burstein J, Lee DS, Alter DA. J Eval Clin Pract. 2006; 12(1):87-93.
Uptake and Outcomes Associated with Cyclooxgenase (COX-2) Inhibitors in Ontario’s Elderly
Comparison of coding of heart failure and comorbidities in administrative and clinical data for use in outcomes research
Lee DS, Donovan L, Austin PC, Gong Y, Liu PP, Rouleau JL, Tu JV. Med Care. 2005; 43(2):182-8.
Comparison of angiotensin-converting enzyme inhibitors in the treatment of congestive heart failure
Tu K, Mamdani M, Kopp A, Lee D. Am J Cardiol. 2005; 95(2):283-6.
Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study
Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA. N Engl J Med. 2004; 351(6):543-51.
Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study
Mamdani M, Juurlink DN, Lee DS, Rochon PA, Kopp A, Naglie G, Austin PC, Laupacis A, Stukel TA. Lancet. 2004; 363(9423):1751-6.
Regional outcomes of heart failure in Canada
Lee DS, Johansen H, Gong Y, Hall RE, Tu JV, Cox JL; Canadian Cardiovascular Outcomes Research Team. Can J Cardiol. 2004; 20(6):599-607.
Trends in heart failure outcomes and pharmacotherapy: 1992 to 2000
Lee DS, Mamdani MM, Austin PC, Gong Y, Liu PP, Rouleau JL, Tu JV. Am J Med. 2004; 116(9):581-9.